Medshine Discovery Inc. has divulged azaspiro compounds acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.

Haisco Pharmaceutical Group Co. Ltd. has identified IL-17A production inhibitors with reduced toxic and side effects.

Mirati Therapeutics Inc. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

The University of California Oakland has disclosed N,N-dimethylamphetamine analogues for the treatment of neurological disorders.

Betta Pharmaceuticals Co. Ltd. has described hypoxia-inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of Von Hippel-Lindau disease, cancer, autoimmune disease and inflammatory disorders.

Phosphatidylinositol 3-kinase α (PI3Kα) inhibitors for the treatment of cancer have been revealed in a Fochon Biosciences Ltd. patent.

Research at Humanwell Healthcare (Group) Co. Ltd. has led to the development of heterocyclic 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of acute lung injury, diabetes, fibrosis, graft-vs.-host disease, heart failure, inflammatory bowel disease, alopecia and osteoporosis, among others.

Teon Therapeutics Inc. has reported 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide...

Bright Angel Therapeutics Inc. has patented heat shock protein 90 inhibitors reported to be useful...

Research at Simcere Zaiming Pharmaceutical Co. Ltd. has led to the development of polycyclic compounds acting as E3 ubiquitin-protein ligase CBL-B inhibitors and thus reported to be useful for the treatment of cancer and autoimmune disease.